// App-Quantinova.ai

1163 : Patient-Reported Treatment Satisfaction with Oral Rivaroxaban Versus Standard Therapy in the Treatment of Acute Symptomatic Pulmonary Embolism

Researchers

Presenter

  • Luke Bamber

Principal Investigators

  • Stefan Cano

  • Maria Wang

  • Anthonie WA Lensing

  • Rupert Bauersachs

Medical Centers

  • Department of Clinical Neuroscience, Peninsula College of Medicine and Dentistry, Plymouth, United Kingdom

  • Clinical Epidemiology and Technology Assessment, University Medical Center, Maastricht, Netherlands

  • Klinikum Darmstadt GmbH

Locations

  • United Kingdom

  • Netherlands

Companies

  • Bayer

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

  • Deep vein thrombosis

  • Pulmonary embolism

Biomarkers

  • N/A

Drug/Treatment

  • rivaroxaban

  • Enoxaparin

  • Enoxaparin sodium

  • Hydroxyzine

Outcome

  • N/A

Study Design

  • open label

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved